Spectral pattern of total creatine and trimethyl ammonium in multiple sclerosis

Creatine and multiple sclerosis

Multiple sclerosis (MS) is a complex and debilitating neurodegenerative disease, with unknown cause(s), unpredictable prognosis, and rather limited treatment options. MS is often accompanied by various metabolic disturbances, with impaired creatine metabolism may play a role in its pathogenesis and the clinical course of the disease. This review summarizes human trials describing alterations in creatine levels in the nervous system and other tissues during MS, affects how certain medications for MS affect brain creatine concentrations, and discusses a possible demand for exogenous creatine as an adjunct therapeutic agent in the management of MS. Creatine metabolism seems to be dysfunctional in MS, indicating a low metabolic state of the brain and other relevant organs in this unpredictable demyelinating disease. A disease-driven brain creatine deficit could be seen as a distinctive pathological facet of severe MS that might be approached with targeted therapies in aim to restore creatine homeostasis.

In vivo H1 MR spectroscopy using 3 Tesla to investigate the metabolic profiles of joint fluids in different types of knee diseases

In vivo proton (H1) magnetic resonance spectroscopy (MRS) has not yet been systematically used to study joint fluids in human knees. The objective of this study, therefore, was to assess the ability of proton MRS to identify the apparent heterogeneous characteristics of metabolic spectra in the joint fluid regions in human knees using a high‐field MRI system. Eighty‐four patients with effusion lesions who were referred for routine knee MR imaging underwent proton MRS with point‐resolved, single‐voxel MR spectroscopy using a clinical 3.0 Tesla MRI system. Thirty‐eight patients were confirmed to have the following: degenerative osteoarthritis, 21 patients (Group 1); traumatic diseases, 12 patients (Group 2); infectious diseases, 4 patients and an inflammatory disease, 1 patient (Group 3). Spectroscopy data were analyzed using the public jMRUI freeware software to obtain lipid metabolites. Nonparametric statistical comparisons were performed to investigate any differences in metabolites among the three disease groups. The major metabolites were vinylic CH=CH lipids around 5.1−5.5 ppm, CH2 lipids around 1.1−1.5 ppm, and CH3 lipids around 0.7−1.0 ppm. Each patient had either a CH=CH lipid peak, CH2 and CH3 lipid peaks, or all three peaks. There were no significant differences among the three groups for the CH3 (p=0.9019), CH2 (p=0.6406), and CH=CH lipids (p=0.5467) and water (p=0.2853); none of the metabolites could differentiate between any of the three types of diseases. The CH2 lipids in the 38 patients who had confirmed fluid characteristics were significantly correlated with CH3 lipids (rho=0.835, p<0.0001). The ratio of CH3 to CH2 was highest in the degenerative disease. In both the degenerative and traumatic diseases, metabolite peaks of the vinylic CH=CH lipids around 5.1−5.5 ppm and of the sum of the CH2 and CH3 lipids around 0.7−1.5 ppm were observed, but in the infectious disease, only a metabolite peak of the sum of the CH2 and CH3 lipids was detected. Although none of the metabolites could statistically significantly differentiate between the three types of diseases, the different lipid metabolite peaks and their ratios in the three disease groups may give us a hint at the different mechanisms of joint fluids in the infectious, degenerative, and traumatic diseases.

PACS number(s): 87.61.Ff, 33.25.+k, 87.14.Cc

Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics

BACKGROUND

'Encephalomyelitis disseminata' (multiple sclerosis) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are both classified as diseases of the central nervous system by the World Health Organization. This review aims to compare the phenomenological and neuroimmune characteristics of MS with those of ME/CFS.

DISCUSSION

There are remarkable phenomenological and neuroimmune overlaps between both disorders. Patients with ME/CFS and MS both experience severe levels of disabling fatigue and a worsening of symptoms following exercise and resort to energy conservation strategies in an attempt to meet the energy demands of day-to-day living. Debilitating autonomic symptoms, diminished cardiac responses to exercise, orthostatic intolerance and postural hypotension are experienced by patients with both illnesses. Both disorders show a relapsing-remitting or progressive course, while infections and psychosocial stress play a large part in worsening of fatigue symptoms. Activated immunoinflammatory, oxidative and nitrosative (O+NS) pathways and autoimmunity occur in both illnesses. The consequences of O+NS damage to self-epitopes is evidenced by the almost bewildering and almost identical array of autoantibodies formed against damaged epitopes seen in both illnesses. Mitochondrial dysfunctions, including lowered levels of ATP, decreased phosphocreatine synthesis and impaired oxidative phosphorylation, are heavily involved in the pathophysiology of both MS and ME/CFS. The findings produced by neuroimaging techniques are quite similar in both illnesses and show decreased cerebral blood flow, atrophy, gray matter reduction, white matter hyperintensities, increased cerebral lactate and choline signaling and lowered acetyl-aspartate levels.

SUMMARY

This review shows that there are neuroimmune similarities between MS and ME/CFS. This further substantiates the view that ME/CFS is a neuroimmune illness and that patients with MS are immunologically primed to develop symptoms of ME/CFS.

Muscle metabolism in Duchenne muscular dystrophy assessed by in vivo proton magnetic resonance spectroscopy

PURPOSE

To investigate the correlation between muscle function and metabolism in muscle tissue of Duchenne muscular dystrophy (DMD) patients by in vivo proton magnetic resonance spectroscopy.

MATERIALS AND METHODS

In this prospective study, we enrolled 8 boys with DMD and 8 healthy volunteers. In vivo proton magnetic resonance spectroscopy of the soleus muscles was performed using a whole-body 3.0-Tesla imaging unit and a knee coil. The levels of trimethyl ammonium (TMA) and total creatine (tCr) were measured. We compared TMA/water, tCr/water, and TMA/tCr ratios, and scores for muscle function in the legs by using a t test.

RESULTS

Fat infiltrated the leg muscles in all patients but no volunteers. All patients had elevated creatine kinase levels. Magnetic resonance spectra of patients and volunteers showed TMA and tCr peaks. Ratios of TMA/water (P = 0.0015), tCr/water (P = 0.0167), and TMA/tCr (P = 0.0017), and muscle function scores (P = 0.0028) were significantly lower in patients than in volunteers. All patients had impaired muscle function, whereas all volunteers had normal function. Muscle function in the legs was negatively correlated with the TMA/tCr ratio (r2 = 0.878).

CONCLUSIONS

Metabolite ratios and muscle function scores were significantly decreased in patients with DMD when compared with normal control subjects. A statistically significant decrease in TMA/tCr ratio in patients with DMD as compared with control subjects was found to correlate with decreased muscle function.

In vivo proton magnetic resonance spectroscopy assessment for muscle metabolism in neuromuscular diseases

Muscle metabolites were obtained by in vivo proton magnetic resonance spectroscopy of 3 patients with Duchenne muscular dystrophy (DMD), 6 patients with spinal muscular atrophy (SMA), and 10 normal volunteers. Patients with DMD and SMA had lower trimethyl amide (TMA)/water and TMA/total creatine (tCr) ratios but normal tCr/water ratios.